Skip to main content
Erschienen in: Clinical and Experimental Medicine 1/2022

10.07.2021 | Original Article

Pancreatic MR imaging and endocrine complications in patients with beta-thalassemia: a single-center experience

verfasst von: Cihangir Sevimli, Yasin Yilmaz, Zuhal Bayramoglu, Rana Gunoz Comert, Nurdan Gul, Memduh Dursun, Zeynep Karakas

Erschienen in: Clinical and Experimental Medicine | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Iron deposition in various organs can cause endocrine complications in patients with transfusion-dependent beta-thalassemia. The aim was to investigate the relationship between endocrine complications and pancreatic iron overload using magnetic resonance imaging (MRI). Forty patients with transfusion-dependent thalassemia (TDT) were enrolled in the study. The magnetic resonance imagings of the patients were performed using a 1.5 Tesla Philips MRI scanner. Two out of three patients had at least one clinical endocrine complication. The rate of iron deposition was 62.5% in liver, and 45% in pancreas tissue, and was 12.5% in heart tissue. Pancreatic T2* and hepatic T2* values were significantly positively correlated (p = 0.006). Pancreatic T2* and ferritin were significantly negatively correlated (p = 0.03). Cardiac T2* values were negatively correlated with fasting blood glucose (p = 0.03). Patients with short stature had significantly higher cardiac iron burden (22.3 vs. 36.6 T2*ms; p 0.01), and patients with hypothyroidism had higher liver iron concentrations (9.9 vs. 6.4 LIC mg/g; p = 0.05). The ferritin level of 841 ng/mL and liver iron concentration (LIC) value of 8.7 mg/g were detected as the threshold level for severe pancreatic iron burden (AUC 70%, p:0.04, AUC 80%, p = 0.002, respectively). Moreover, males were found to have decreased pancreas T2* values compared with the values in females (T2* 19.3 vs. 29.9, p = 0.05). Patients with higher ferritin levels over than 840 ng/mL should be closely monitored for pancreatic iron deposition, and patients with endocrine complications should be assessed in terms of cardiac iron burden.
Literatur
1.
Zurück zum Zitat Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V. Guidelines for the management of transfusion-dependent thalassaemia (TDT). 3rd ed. Thalassaemia International Federation TIF Publication; 2014. p. 17–65. Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V. Guidelines for the management of transfusion-dependent thalassaemia (TDT). 3rd ed. Thalassaemia International Federation TIF Publication; 2014. p. 17–65.
2.
Zurück zum Zitat Marcon A, Motta I, Taher AT, Cappellini MD. Clinical complications and their management. Hematol Oncol Clin North Am. 2018;32(2):223–36.CrossRef Marcon A, Motta I, Taher AT, Cappellini MD. Clinical complications and their management. Hematol Oncol Clin North Am. 2018;32(2):223–36.CrossRef
3.
Zurück zum Zitat De Sanctis V, Roos M, Gasser T, Fortini M, Raiola G, Galati MC. Italian working group on endocrine complications in non-endocrine diseases. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia. J Pediatr Endocrinol Metab. 2006;19:471–80.PubMed De Sanctis V, Roos M, Gasser T, Fortini M, Raiola G, Galati MC. Italian working group on endocrine complications in non-endocrine diseases. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia. J Pediatr Endocrinol Metab. 2006;19:471–80.PubMed
4.
Zurück zum Zitat Oudit GY, Trivieri MG, Khaper N, Liu PP, Backx PH. Role of L-type Ca2_ channels in iron transport and iron-overload cardiomyopathy. J Mol Med. 2006;84(5):349–64.CrossRef Oudit GY, Trivieri MG, Khaper N, Liu PP, Backx PH. Role of L-type Ca2_ channels in iron transport and iron-overload cardiomyopathy. J Mol Med. 2006;84(5):349–64.CrossRef
5.
Zurück zum Zitat Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101(11):4632–9.CrossRef Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101(11):4632–9.CrossRef
6.
Zurück zum Zitat Noetzli LJ, Papudesi J, Coates TD, Wood JC. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood. 2009;114(19):4021–6.CrossRef Noetzli LJ, Papudesi J, Coates TD, Wood JC. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood. 2009;114(19):4021–6.CrossRef
7.
Zurück zum Zitat Mokhtar GM, Ibrahim WE, Elbarbary NS, Matter RM, Ibrahim AS, Sayed SM. Pancreatic functions in adolescents with beta thalassemia major could predict cardiac and hepatic iron loading: relation to T2-star (T2*) magnetic resonance imaging. J Investig Med. 2016;64(3):771–81.CrossRef Mokhtar GM, Ibrahim WE, Elbarbary NS, Matter RM, Ibrahim AS, Sayed SM. Pancreatic functions in adolescents with beta thalassemia major could predict cardiac and hepatic iron loading: relation to T2-star (T2*) magnetic resonance imaging. J Investig Med. 2016;64(3):771–81.CrossRef
8.
Zurück zum Zitat Wood JC. Impact of iron assessment by MRI. Hematol Am Soc Hematol Educ Program. 2011;2011:443–50.CrossRef Wood JC. Impact of iron assessment by MRI. Hematol Am Soc Hematol Educ Program. 2011;2011:443–50.CrossRef
9.
Zurück zum Zitat Perifanis V, Christoforidis A, Vlachaki E, et al. Comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with beta-thalassemia major. Int J Hematol. 2007;86(5):385–9.CrossRef Perifanis V, Christoforidis A, Vlachaki E, et al. Comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with beta-thalassemia major. Int J Hematol. 2007;86(5):385–9.CrossRef
10.
Zurück zum Zitat Au W-Y, Lam W-M, Chu W, et al. A T2* magnetic resonance imaging study of pancreatic iron overload in thalassemia major. Haematologica. 2008;93(1):116–9.CrossRef Au W-Y, Lam W-M, Chu W, et al. A T2* magnetic resonance imaging study of pancreatic iron overload in thalassemia major. Haematologica. 2008;93(1):116–9.CrossRef
11.
Zurück zum Zitat deAssis RA, Ribeiro AA, Kay FU, Rosemberg LA, Nomura CH, Loggetto SR, et al. Pancreatic iron stores assessed by magnetic resonance imaging (MRI) in beta thalassemic patients. Eur J Radiol. 2012;81(7):1465–70.CrossRef deAssis RA, Ribeiro AA, Kay FU, Rosemberg LA, Nomura CH, Loggetto SR, et al. Pancreatic iron stores assessed by magnetic resonance imaging (MRI) in beta thalassemic patients. Eur J Radiol. 2012;81(7):1465–70.CrossRef
12.
Zurück zum Zitat Restaino G, Meloni A, Positano V, et al. Regional and global pancreatic T*2 MRI for iron overload assessment in a large cohort of healthy subjects: normal values and correlation with age and gender. MagnReson Med. 2011;65(3):764–9.CrossRef Restaino G, Meloni A, Positano V, et al. Regional and global pancreatic T*2 MRI for iron overload assessment in a large cohort of healthy subjects: normal values and correlation with age and gender. MagnReson Med. 2011;65(3):764–9.CrossRef
13.
Zurück zum Zitat Meloni A, Restaino G, Missere M, et al. Pancreatic iron overload by T2* MRI in a large cohort of well treated thalassemia major patients: can it tell us heart iron distribution and function? Am J Hematol. 2015;90(9):E189–90.CrossRef Meloni A, Restaino G, Missere M, et al. Pancreatic iron overload by T2* MRI in a large cohort of well treated thalassemia major patients: can it tell us heart iron distribution and function? Am J Hematol. 2015;90(9):E189–90.CrossRef
14.
Zurück zum Zitat Sirlin CB, Reeder SB. Magnetic resonance imaging quantification of liver iron. Magn Reson Imaging Clin N Am. 2010;18(3):359–81.CrossRef Sirlin CB, Reeder SB. Magnetic resonance imaging quantification of liver iron. Magn Reson Imaging Clin N Am. 2010;18(3):359–81.CrossRef
15.
Zurück zum Zitat De Sanctis V, Soliman AT, Elsedfy H, Skordis N, Kattamis C, Angastiniotis M, et al. Growth and endocrine disorders in thalassemia: The international network on endocrine complications in Thalassemia (I-CET) position statement and guidelines. Indian J Endocrinol Met. 2013;17(1):8–18.CrossRef De Sanctis V, Soliman AT, Elsedfy H, Skordis N, Kattamis C, Angastiniotis M, et al. Growth and endocrine disorders in thalassemia: The international network on endocrine complications in Thalassemia (I-CET) position statement and guidelines. Indian J Endocrinol Met. 2013;17(1):8–18.CrossRef
16.
Zurück zum Zitat De Sanctis V, Eleftheriou A, Malaventura C. Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia. Prevalence of endocrine complications and short tature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev. 2004;2:249–55.PubMed De Sanctis V, Eleftheriou A, Malaventura C. Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia. Prevalence of endocrine complications and short tature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev. 2004;2:249–55.PubMed
17.
Zurück zum Zitat Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, et al. Survival and complications in Thalassemia Major. Ann NY Acad Sci. 2005;1054:40–7.CrossRef Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, et al. Survival and complications in Thalassemia Major. Ann NY Acad Sci. 2005;1054:40–7.CrossRef
18.
Zurück zum Zitat Li CK, Luk CW, Ling SC, Chik KW, Yuen HL, Shing MM, et al. Morbidity and mortality patterns of thalassaemia major patients in Hong Kong: retrospective study. Hong Kong Med J. 2002;8:255–60.PubMed Li CK, Luk CW, Ling SC, Chik KW, Yuen HL, Shing MM, et al. Morbidity and mortality patterns of thalassaemia major patients in Hong Kong: retrospective study. Hong Kong Med J. 2002;8:255–60.PubMed
19.
Zurück zum Zitat Isik P, Yarali N, Tavil B, Demirel F, Karacam GB, Sac RU, et al. Endocrinopathies in Turkish children with Beta thalassemia major: results from a single center study. Pediatr Hematol Oncol. 2014;31:607–15.CrossRef Isik P, Yarali N, Tavil B, Demirel F, Karacam GB, Sac RU, et al. Endocrinopathies in Turkish children with Beta thalassemia major: results from a single center study. Pediatr Hematol Oncol. 2014;31:607–15.CrossRef
20.
Zurück zum Zitat Altincik A, Akin M. Prevalence of endocrinopathies in Turkish children with β-thalassemia major: a single-center study. J Pediatr Hematol Oncol. 2016;38(5):389–93.CrossRef Altincik A, Akin M. Prevalence of endocrinopathies in Turkish children with β-thalassemia major: a single-center study. J Pediatr Hematol Oncol. 2016;38(5):389–93.CrossRef
21.
Zurück zum Zitat Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman MH, Holland FJ. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. N Engl J Med. 1990;323(11):713–9.CrossRef Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman MH, Holland FJ. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. N Engl J Med. 1990;323(11):713–9.CrossRef
22.
Zurück zum Zitat Gamberini MR, De Sanctis V, Gilli G. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev. 2008;6(Suppl 1):158–69.PubMed Gamberini MR, De Sanctis V, Gilli G. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev. 2008;6(Suppl 1):158–69.PubMed
23.
Zurück zum Zitat Bilgin BK, Yozgat AK, Isik P, et al. The effect of deferasirox on endocrine complications in children with thalassemia. Pediatr Hematol Oncol. 2020;37(6):1–10.CrossRef Bilgin BK, Yozgat AK, Isik P, et al. The effect of deferasirox on endocrine complications in children with thalassemia. Pediatr Hematol Oncol. 2020;37(6):1–10.CrossRef
24.
Zurück zum Zitat Kolnagou A, Natsiopoulos K, Kleanthous M, Ioannou A, Kontoghiorghes GJ. Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*. Toxicol Mech Methods. 2013;23(1):48–56.CrossRef Kolnagou A, Natsiopoulos K, Kleanthous M, Ioannou A, Kontoghiorghes GJ. Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*. Toxicol Mech Methods. 2013;23(1):48–56.CrossRef
25.
Zurück zum Zitat Simcox JA, McClain DA. Iron and diabetes risk. Cell Metab. 2013;17(3):329–41.CrossRef Simcox JA, McClain DA. Iron and diabetes risk. Cell Metab. 2013;17(3):329–41.CrossRef
26.
Zurück zum Zitat Tzoulis P, Shah F, Jones R, et al. Joint diabetes thalassaemia clinic: an effective new model of care. Hemoglobin. 2014;38:104–10.CrossRef Tzoulis P, Shah F, Jones R, et al. Joint diabetes thalassaemia clinic: an effective new model of care. Hemoglobin. 2014;38:104–10.CrossRef
27.
Zurück zum Zitat Tzoulis P. Review of endocrine complications in adult patients with β-thalassaemia major. Thalassemia Reports. 2014;4:4871.CrossRef Tzoulis P. Review of endocrine complications in adult patients with β-thalassaemia major. Thalassemia Reports. 2014;4:4871.CrossRef
28.
Zurück zum Zitat Fernandes JL. MRI for iron overload in thalassemia. Hematol Oncol Clin North Am. 2018;32(2):277–95.CrossRef Fernandes JL. MRI for iron overload in thalassemia. Hematol Oncol Clin North Am. 2018;32(2):277–95.CrossRef
29.
Zurück zum Zitat Barrera CA, Otero HJ, Hartung HD, Biko DM, Serai SD. Protocol optimization for cardiac and liver iron content assessment using MRI: what sequence should I use? Clin Imaging. 2019;56:52–7.CrossRef Barrera CA, Otero HJ, Hartung HD, Biko DM, Serai SD. Protocol optimization for cardiac and liver iron content assessment using MRI: what sequence should I use? Clin Imaging. 2019;56:52–7.CrossRef
30.
Zurück zum Zitat Sheth S, Allen CJ, Farrell DE, et al. Measurement of the liver iron concentration in transfusional iron overload by MRI R2* and by high-transition-temperature superconducting magnetic susceptometry. Clin Imaging. 2019;55:65–70.CrossRef Sheth S, Allen CJ, Farrell DE, et al. Measurement of the liver iron concentration in transfusional iron overload by MRI R2* and by high-transition-temperature superconducting magnetic susceptometry. Clin Imaging. 2019;55:65–70.CrossRef
31.
Zurück zum Zitat Pepe A, Pistoia L, Gamberini MR, Cuccia L, Peluso A, Messina G, Spasiano A, et al. The close link of pancreatic iron with glucose metabolism and with cardiac complications in thalassemia major: a large. Multicenter Observational Study Diabetes Care. 2020;43(11):2830–9.PubMed Pepe A, Pistoia L, Gamberini MR, Cuccia L, Peluso A, Messina G, Spasiano A, et al. The close link of pancreatic iron with glucose metabolism and with cardiac complications in thalassemia major: a large. Multicenter Observational Study Diabetes Care. 2020;43(11):2830–9.PubMed
32.
Zurück zum Zitat Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876–84.CrossRef Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876–84.CrossRef
33.
Zurück zum Zitat Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R, et al. American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and Imaging. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation. 2013;128(3):281–308.CrossRef Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R, et al. American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and Imaging. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation. 2013;128(3):281–308.CrossRef
34.
Zurück zum Zitat Pepe A, Meloni A, Pistoia L, Cuccia L, Gamberini MR, Lisi R, et al. MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine. Br J Haematol. 2018;183(5):783–95.CrossRef Pepe A, Meloni A, Pistoia L, Cuccia L, Gamberini MR, Lisi R, et al. MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine. Br J Haematol. 2018;183(5):783–95.CrossRef
35.
Zurück zum Zitat Pepe A, Meloni A, Rossi G, Caruso V, Cuccia L, Spasiano A, et al. Cardiac complications and diabetes in thalassaemia major: a large historical multicentre study. Br J Haematol. 2013;163(4):520–7.CrossRef Pepe A, Meloni A, Rossi G, Caruso V, Cuccia L, Spasiano A, et al. Cardiac complications and diabetes in thalassaemia major: a large historical multicentre study. Br J Haematol. 2013;163(4):520–7.CrossRef
36.
Zurück zum Zitat Kyriakou A, Skordis N. Thalassaemia and aberrations of growth and puberty. Mediterr J Hematol Infect Dis. 2009;1(1):e2009003.PubMedPubMedCentral Kyriakou A, Skordis N. Thalassaemia and aberrations of growth and puberty. Mediterr J Hematol Infect Dis. 2009;1(1):e2009003.PubMedPubMedCentral
37.
Zurück zum Zitat Soliman AT, Khalafallah H, Ashour R. Growth and factors affecting it in thalassemia major. Hemoglobin. 2009;33(Suppl 1):S116–26.CrossRef Soliman AT, Khalafallah H, Ashour R. Growth and factors affecting it in thalassemia major. Hemoglobin. 2009;33(Suppl 1):S116–26.CrossRef
Metadaten
Titel
Pancreatic MR imaging and endocrine complications in patients with beta-thalassemia: a single-center experience
verfasst von
Cihangir Sevimli
Yasin Yilmaz
Zuhal Bayramoglu
Rana Gunoz Comert
Nurdan Gul
Memduh Dursun
Zeynep Karakas
Publikationsdatum
10.07.2021
Verlag
Springer International Publishing
Erschienen in
Clinical and Experimental Medicine / Ausgabe 1/2022
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-021-00735-7

Weitere Artikel der Ausgabe 1/2022

Clinical and Experimental Medicine 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.